Contineum Therapeutics, INC Form 4 insider transactions

Carmine N. Stengone, CEO and President and a Director of Contineum Therapeutics, Inc., sold 2,500 shares of common stock on August 3, 2026 for $16.01 per share.

Contineum Therapeutics reports insider transactions involving Class A Common Stock and stock options by Chief Scientific Officer Daniel S. Lorrain.

Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., reported the sale of 2,500 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics reports insider transactions by Chief Scientific Officer Daniel S. Lorrain, involving stock option exercises and sales under a 10b5-1 plan.

Contineum Therapeutics' CMO & Head of Development, Tim Watkins, sold 10,833 shares of Class A Common Stock for approximately $16.02 per share, as part of a pre-arranged 10b5-1 trading plan.

Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., reported transactions involving Class A Common Stock and stock options on June 30, 2026, executed under a Rule 10b5-1 trading plan.

Contineum Therapeutics reports a stock option grant to Director Gines Diego Miralles as part of the company's Non-Employee Director Compensation Program.

Lori Lyons-Williams, a Director at Contineum Therapeutics, Inc., received a stock option grant for 19,000 shares of Class A Common Stock.

Contineum Therapeutics, Inc. reports the grant of stock options to Director Olivia C. Ware under its 2024 Equity Incentive Plan.

Evert Schimmelpennink, a Director at Contineum Therapeutics, Inc., was granted 19,000 stock options.

Contineum Therapeutics, Inc. reports the grant of stock options to Director Troy A. Ignelzi under the 2024 Equity Incentive Plan.

Contineum Therapeutics, Inc. reports the grant of 19,000 stock options to Director Todd R. Brady under the 2024 Equity Incentive Plan.

Contineum Therapeutics, Inc. reports the grant of stock options to Director Sarah Boyce under its 2024 Equity Incentive Plan.

Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Contineum Therapeutics common stock via a 10b5-1 plan.

Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Contineum Therapeutics common stock via a 10b5-1 trading plan.

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A Common Stock for $13.43 per share under a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock for a weighted average price of $15.0084 per share under a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics' CMO and Head of Development, Tim Watkins, exercised options and sold 3,611 shares of Class A Common Stock for a profit on March 2, 2026, under a pre-arranged 10b5-1 plan.

Contineum Therapeutics CEO and President Carmine N. Stengone executed planned sales of Class A Common Stock totaling 7,100 shares in late February 2026.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, executed pre-planned option exercises and subsequent sales of Class A Common Stock on February 24 and 25, 2026.

Contineum Therapeutics CEO and President Carmine N. Stengone exercised stock options and immediately sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised stock options and subsequently sold an equal number of shares on February 11, 2026, under a pre-arranged 10b5-1 plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock in pre-arranged transactions.

Contineum Therapeutics, Inc. granted stock options for 206,411 shares to General Counsel John Stephen Healy at an exercise price of $14.26.

Contineum Therapeutics' CFO, Peter Slover, received a grant of 192,000 stock options with an exercise price of $14.26, vesting over 48 months.

Contineum Therapeutics' CEO and President, Carmine N. Stengone, was granted 445,000 stock options at an exercise price of $14.26, vesting over 48 months.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, was granted 166,500 stock options with an exercise price of $14.26, vesting over 48 months.

Contineum Therapeutics' CMO and Head of Development, Tim Watkins, exercised stock options, sold shares, and was granted new options under a pre-arranged trading plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock on January 5, 2026, under a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics' CMO and Head of Development, Tim Watkins, exercised stock options and immediately sold 3,611 shares of Class A Common Stock.